T. Rowe Price Discloses 5% Stake in Qiagen

An announcement from Qiagen ( (QGEN) ) is now available.

Qiagen has disclosed that the Dutch financial regulator AFM notified the company of a substantial shareholding by T. Rowe Price Group, Inc., effective from a transaction dated May 6, 2026. According to the AFM register, T. Rowe Price holds a 5% capital and voting interest in Qiagen through indirect holdings in ordinary shares and New York shares managed by its affiliates.

The notification underscores growing institutional interest in Qiagen’s stock, potentially supporting liquidity and signaling confidence from a major global asset manager. Qiagen emphasized that it is not responsible for the accuracy of the AFM data, which originates from the regulator’s public register.

The most recent analyst rating on (QGEN) stock is a Buy with a $49.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

More about Qiagen

Qiagen N.V., based in Venlo, Netherlands, operates in the life sciences and molecular diagnostics industry, providing sample and assay technologies used in research, pharmaceuticals and clinical testing. Its shares are listed on several European exchanges as well as on the NYSE and Swiss markets, reflecting a broad international investor base and active trading profile.

Average Trading Volume: 2,017,406

Technical Sentiment Signal: Sell

Current Market Cap: $6.94B

See more data about QGEN stock on TipRanks’ Stock Analysis page.